LabGenomics announced on the 4th that it has launched the miscarriage cause analysis NGS (Next-Generation Sequencing) test, Pre-MomGuard. The name adds the meaning of "Pre" to the existing LabGenomics product MomGuard, symbolizing encouragement for pregnant women who have experienced miscarriage to try again.
Pre-MomGuard identifies chromosomal abnormalities through tissue from the miscarried fetus. Utilizing NGS technology, which rapidly and accurately analyzes large amounts of DNA (genetic) information, it tests for numerical and structural chromosomal abnormalities. The test results (TAT) can be obtained within 7 days, which is more than twice as fast as the average of other companies.
According to the National Health Insurance Service and Statistics Korea, in 2022, the number of births in South Korea was approximately 250,000, and the number of miscarriages was 90,000, accounting for about 36%. About 80% of natural miscarriages occur within 12 weeks of pregnancy, and more than half are known to be due to fetal chromosomal abnormalities.
The company stated, "Since the likelihood of miscarriage increases with repetition, identifying the cause in advance is very important," and added, "We will contribute to solving the low birth rate issue through various diagnostic products that support the health of women, including mothers."
They continued, "We have diversified our portfolio alongside existing core products such as MomGuard, EnfantGuard, IMS (newborn screening), and PinkBiome in the field of obstetrics and gynecology molecular diagnostics."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
